Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Axcella Health Inc. (AXLA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ...
08/18/2023 ARS Form ARS - Annual Report to Security Holders:
08/18/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/07/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/04/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
06/29/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previous...
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
02/14/2023 SC 13G/A HarbourVest Partners L.P. reports a 8.4% stake in Axcella Health Inc.
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in AXCELLA HEALTH INC
12/15/2022 8-K Quarterly results
11/01/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/01/2022 8-K Quarterly results
10/17/2022 SC 13D/A Flagship VentureLabs IV, LLC reports a 39.8% stake in AXCELLA HEALTH INC.
10/13/2022 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Letter re: Securities Registered under Registration Statement on Form S-3",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of October 13, 2022, between Axcella Health Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser a..."
10/13/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/29/2022 8-K Quarterly results
09/23/2022 D Form D - Notice of Exempt Offering of Securities:
09/23/2022 SC 13D/A Flagship VentureLabs IV, LLC reports a 35.8% stake in AXCELLA HEALTH INC.
09/23/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "SECURITIES PURCHASE AGREEMENT",
"CONVERTIBLE PROMISSORY NOTE AXCELLA HEALTH INC. $[ ] New York, New York No. [ ] [ ] FOR VALUE RECEIVED, the undersigned, Axcella Health Inc., a Delaware corporation , hereby unconditionally promises to pay to [ ] or its registered assigns at the address specified in the Purchase Agreement in lawful money of the United States and in immediately available funds, the principal sum ofDOLLARS AND ZERO CENTS , together with interest as set forth in the Purchase Agreement until the date on which the principal amount is paid in full, converted in whole or cancelled in accordance with the terms of the Purchase Agreement. Amounts evidenced hereby shall be paid in the amounts and on the dates specified in Section 3 of the Purchase Agreement. This Note: is one of a series of similar Notes issued pursu..."
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/12/2022 8-K Quarterly results
08/02/2022 8-K Investor presentation
Docs: "Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID",
"NASDAQ: AXLA Axcella Therapeutics Phase 2A Long COVID Study Results Presentation Bill Hinshaw"
05/26/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/07/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/07/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/30/2022 10-K Annual Report for the period ended December 31, 2021
03/30/2022 8-K Quarterly results
Docs: "Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy